World J Gastroentero
-
World J Gastroentero · Dec 2008
Magnolol attenuates sepsis-induced gastrointestinal dysmotility in rats by modulating inflammatory mediators.
To investigate the protective effects of magnolol on sepsis-induced inflammation and intestinal dysmotility. ⋯ Magnolol prevents sepsis-induced suppression of intestinal motility in rats. The potential mechanism of this benefit of magnolol appears to be modulation of self-amplified inflammatory events and block of oxidative stress in the intestine.
-
World J Gastroentero · Dec 2008
Clinical outcome of Fitz-Hugh-Curtis syndrome mimicking acute biliary disease.
To analyze the clinical characteristics of patients diagnosed with Fitz-Hugh-Curtis syndrome. ⋯ For women of childbearing age with acute pain in the upper right abdomen alone or together with pain in the lower abdomen, Fitz-Hugh-Curtis syndrome should be considered during differential diagnosis. Moreover, in cases suspected to be Fitz-Hugh-Curtis syndrome, abdominal CT, rather than abdominal sonography, assists in the diagnosis.
-
To investigate the effects and possible mechanisms of Wy14643 on hepatic ischemia-reperfusion (I/R) injury in rats. ⋯ Wy14643 pretreatment exerts significant protection against hepatic I/R injury in rats. The protective effects are possibly associated with enhancement of anti-oxidant and inhibition inflammation response.
-
World J Gastroentero · Oct 2008
Gardenia jasminoides protects against cerulein-induced acute pancreatitis.
To investigate the effect of Gardenia jasminoides (GJ) on cerulein-induced acute pancreatitis (AP) in mice. ⋯ These results suggest that GJ attenuated the severity of AP as well as pancreatitis-associated lung injury.
-
World J Gastroentero · Sep 2008
Comparative StudyFecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease.
To evaluate fecal calprotectin (FC) as a surrogate marker of treatment outcome of relapse of inflammatory bowel disease (IBD) and, to compare FC with fecal myeloperoxidase (MPO) and fecal eosinophil protein X (EPX). ⋯ A normalised FC level has the potential to be used as a surrogate marker for successful treatment outcome in IBD patients. However, patients with persistent elevation of FC levels need further evaluation. FC and MPO provide superior discrimination than EPX in IBD treatment outcome.